Intravenous administration of adenosine triphosphate and phosphocreatine combined with fluoxetine in major depressive disorder: protocol for a randomized, double-blind, placebo-controlled pilot study

Pilot Study ◽

Depressive Disorder ◽

Adenosine Triphosphate ◽

Intravenous Administration ◽

Major Depressive ◽

Double Blind ◽

Efficacy of vitamin C as an adjunct to fluoxetine therapy in pediatric major depressive disorder: a randomized, double-blind, placebo-controlled pilot study

Nutrition Journal ◽

10.1186/1475-2891-12-31 ◽

2013 ◽

Vol 12 (1) ◽

Cited By ~ 43

Author(s):

Mostafa Amr ◽

Ahmed El-Mogy ◽

Tarek Shams ◽

Karen Vieira ◽

Shaheen E Lakhan

Keyword(s):

Pilot Study ◽

Vitamin C ◽

Depressive Disorder ◽

Major Depressive ◽

Double Blind ◽

Double Blind Placebo ◽

Fluoxetine Therapy

Effi cacy of Vitamin C as an Adjunct to Fluoxetine Therapy in Pediatric Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Pilot Study

Clinical Nutrition ◽

10.1201/b16308-9 ◽

2013 ◽

pp. 69-86

Keyword(s):

Pilot Study ◽

Vitamin C ◽

Depressive Disorder ◽

Major Depressive ◽

Double Blind ◽

Double Blind Placebo ◽

Fluoxetine Therapy

Addition of eicosapentaenoic acid to maintenance anti-depressant therapy in diabetes patients with major depressive disorder: a double-blind, placebo-controlled pilot study

http://isrctn.org/> ◽

10.1186/isrctn30877831 ◽

2012 ◽

Cited By ~ 1

Author(s):

F. Pouwer

Keyword(s):

Pilot Study ◽

Depressive Disorder ◽

Eicosapentaenoic Acid ◽

Major Depressive ◽

Double Blind ◽

Double Blind Placebo ◽

Diabetes Patients

Faculty Opinions recommendation of Omega-3 fatty acids for major depressive disorder during pregnancy: results from a randomized, double-blind, placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1103835.559964 ◽

2008 ◽

Author(s):

Deborah Kim

Keyword(s):

Fatty Acids ◽

Depressive Disorder ◽

Controlled Trial ◽

Omega 3 Fatty Acids ◽

Omega 3 ◽

Major Depressive ◽

Double Blind ◽

Statement of Retraction: Efficacy and safety of vortioxetine for the treatment of major depressive disorder: a randomised double-blind placebo-controlled study

International Journal of Psychiatry in Clinical Practice ◽

10.1080/13651501.2021.1950437 ◽

2021 ◽

pp. 1-1

Keyword(s):

Depressive Disorder ◽

Controlled Study ◽

Efficacy And Safety ◽

Major Depressive ◽

Double Blind ◽

Randomized, double-blind, placebo-controlled 8-week trial of the efficacy, safety, and tolerability of 5, 10, and 20 mg/day vortioxetine in adults with major depressive disorder

Psychiatry and Clinical Neurosciences ◽

10.1111/pcn.12565 ◽

2017 ◽

Vol 72 (2) ◽

pp. 64-72 ◽

Cited By ~ 4

Author(s):

Akira Nishimura ◽

Yutaka Aritomi ◽

Kiyofumi Sasai ◽

Tadayuki Kitagawa ◽

Atul R. Mahableshwarkar

Keyword(s):

Depressive Disorder ◽

Major Depressive ◽

Double Blind ◽

A Randomized, Double-Blind, Placebo-Controlled Trial of Escitalopram in Patients with Asthma and Major Depressive Disorder

The Journal of Allergy and Clinical Immunology In Practice ◽

10.1016/j.jaip.2018.01.010 ◽

2018 ◽

Vol 6 (5) ◽

pp. 1604-1612 ◽

Cited By ~ 12

Author(s):

E. Sherwood Brown ◽

Nasreen Sayed ◽

Erin Van Enkevort ◽

Alexandra Kulikova ◽

Alyson Nakamura ◽

...

Keyword(s):

Depressive Disorder ◽

Controlled Trial ◽

Major Depressive ◽

Double Blind ◽

Effect of prebiotic and probiotic supplementation on circulating pro-inflammatory cytokines and urinary cortisol levels in patients with major depressive disorder: A double-blind, placebo-controlled randomized clinical trial

Journal of Functional Foods ◽

10.1016/j.jff.2018.11.041 ◽

2019 ◽

Vol 52 ◽

pp. 596-602 ◽

Cited By ~ 9

Author(s):

Asma Kazemi ◽

Ahmad Ali Noorbala ◽

Kamal Azam ◽

Kurosh Djafarian

Keyword(s):

Clinical Trial ◽

Depressive Disorder ◽

Inflammatory Cytokines ◽

Urinary Cortisol ◽

Major Depressive ◽

Probiotic Supplementation ◽

Double Blind ◽

Double Blind Placebo ◽

Pro Inflammatory Cytokines

A randomized, double-blind, placebo-controlled, dose-ranging study of lisdexamfetamine dimesylate augmentation for major depressive disorder in adults with inadequate response to antidepressant therapy

Journal of Psychopharmacology ◽

10.1177/0269881117722998 ◽

2017 ◽

Vol 31 (9) ◽

pp. 1190-1203 ◽

Cited By ~ 5

Author(s):

Cynthia Richards ◽

Dan V Iosifescu ◽

Rajnish Mago ◽

Elias Sarkis ◽

James Reynolds ◽

...

Keyword(s):

Depressive Disorder ◽

Antidepressant Therapy ◽

Inadequate Response ◽

Major Depressive ◽

Lisdexamfetamine Dimesylate ◽

Double Blind ◽

Double Blind Placebo ◽

Dose Ranging

P.1.030 Double-blind, placebo-controlled,multicenter study evaluating nemifitide, a new pentapeptide antidepressant, when given daily or every other day for three weeks in the treatment of major depressive disorder

European Neuropsychopharmacology ◽

10.1016/s0924-977x(05)80258-5 ◽

2005 ◽

Vol 15 ◽

pp. S119

Author(s):

J.P. Feighner ◽

L. Sverdlov ◽

J. Hlavka ◽

G. Nicolau ◽

G. Tonelli ◽

...

Keyword(s):

Depressive Disorder ◽

Multicenter Study ◽

Major Depressive ◽

Double Blind ◽